Dexrazoxane reduces heart damage in pediatric cancer survivors years after treatment
CancerHeart Disease
Summary
A new study demonstrates that dexrazoxane, a cardioprotective medication, significantly reduces heart damage caused by chemotherapy in pediatric cancer patients even 15 years or more after treatment completion. Chemotherapy drugs, while effective at fighting cancer, can cause long-term cardiac complications in survivors. This finding is important for pediatric cancer survivors who remain at risk for heart disease decades after their initial treatment. The protective effects of dexrazoxane suggest it could improve long-term health outcomes and quality of life for this vulnerable population.
